Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

NCT07223593 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medication orforglipron in adults who have peripheral artery disease.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 1,205 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-10 · est. completion 2028-06

Where 138 sites · Argentina, Australia, Brazil, Canada, China, France, India, Japan, Netherlands, Poland, Puerto Rico, Slovakia, South Korea, Taiwan, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT07223593 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Percent Change from Baseline in Maximum Walking Distance
Sponsor	Eli Lilly and Company
Conditions studied	Peripheral Arterial Disease
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07223593 ↗